Tag: cases

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August 3, 2026 lead plaintiff deadline.

LOS ANGELES, June 26, 2026 (GLOBE NEWSWIRE) -- XMax Inc. (Nasdaq: XMAX) ("XMax" or the "Company") today announced a significant commercial milestone in its artificial intelligence business, reporting that since launching its AI platform initiative, the Company has executed multiple AI model API service agreements with an aggregate contractual value of up to approximately US$25 million, subject to actual service usage and consumption levels.

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of UP Fintech Holding Limited (NASDAQ: TIGR) resulting from allegations that UP Fintech may have issued materially misleading business information to the investing public.

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

This strategic initiative with the Ministry of Economy of Ukraine aims to fast-track digital infrastructure development, unlock scalable AI adoption, and underpin sustainable long-term economic growth.

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4

Ninth Annual Program Honors the AI Innovators Shaping the Next Era of Global Innovation